Novartis Japan Launches Four New Products
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Novartis' Japanese subsidiary, Novartis Pharma K.K. launched four products in the Japanese market March 13. The new drugs are Xolair, Co-Dio, Tasigna and Lucentis. The first asthma antibody drug approved in Japan, Xolair (omalizumab), is used to treat severe asthma that can not be controlled by other drugs and is administrated every other week or every four weeks. Co-Dio is a hypertension combo drug of valsartan and hydrochlorothiazide. Tasigna (nilotinib) is indicated for adult chronic myelogenous leukemia patients resistant or intolerant to prior therapy. Antibody drug Lucentis (ranibizumab) treats age-related macular degeneration. The four products were approved in Japan in January. (Click here for more - Japanese language